N-glycosylated VEGFR2 also interacted with galectin-1 and blocked the interaction between anti-VEGFR antibody and VEGFR2, leading to decreased efficacy of anti-VEGF cancer therapy [12]. This evidence concerns the gene KDR and cancer.